Literature DB >> 17035743

Immunological effects of macrolides.

M T Labro1.   

Abstract

Various reviews have highlighted the potential immuno-modulating properties of macrolides. Recent data in this field raise the possibility of new therapeutic prospects in cancer and inflammatory diseases (cystic fibrosis, asthma, atherosclerosis, etc.). Advances have also been made in our understanding of the interactions between macrolides and host immune effectors, particularly phagocytes. The third millennium should see exciting new uses of macrolides.

Entities:  

Year:  1998        PMID: 17035743     DOI: 10.1097/00001432-199812000-00006

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  10 in total

1.  Cellular uptake of two fluoroketolides, HMR 3562 and HMR 3787, by human polymorphonuclear neutrophils in vitro.

Authors:  H Abdelghaffar; D Vazifeh; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 2.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils.

Authors:  D Vazifeh; A Bryskier; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin.

Authors:  D Vazifeh; H Abdelghaffar; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  The macrolide roxithromycin impairs NADPH oxidase activation and alters translocation of its cytosolic components to the neutrophil membrane in vitro.

Authors:  Houria Abdelghaffar; Catherine Babin-Chevaye; Marie-Thérèse Labro
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  In vitro effects of ciprofloxacin and roxithromycin on apoptosis of jurkat T lymphocytes.

Authors:  Yong-Taek Jun; Hee-Jung Kim; Min-Jin Song; Ji-Hyang Lim; Dong-Gun Lee; Kyung-Ja Han; Su-Mi Choi; Jin-Hong Yoo; Wan-Shik Shin; Jung-Hyun Choi
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

7.  Inhibition of secretion of interleukin-1alpha and tumor necrosis factor alpha by the ketolide antibiotic telithromycin.

Authors:  Fausto G Araujo; Teri L Slifer; Jack S Remington
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Interaction of the new ketolide ABT-773 (cethromycin) with human polymorphonuclear neutrophils and the phagocytic cell line PLB-985 in vitro.

Authors:  Marie Thérèse Labro; Houria Abdelghaffar; Catherine Babin-Chevaye
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 9.  Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.

Authors:  Rosa María Girón Moreno; Marta García-Clemente; Layla Diab-Cáceres; Adrián Martínez-Vergara; Miguel Ángel Martínez-García; Rosa Mar Gómez-Punter
Journal:  Antibiotics (Basel)       Date:  2021-04-23

Review 10.  Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives.

Authors:  Cinzia Rotondo; Giuseppe Lopalco; Florenzo Iannone; Antonio Vitale; Rosaria Talarico; Mauro Galeazzi; Giovanni Lapadula; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2015-06-22       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.